Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

BioMarin Pharmaceutical Inc. (BMRN) had Revenue of $825.41M for the most recently reported fiscal quarter, ending 2025-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	$825.41M
Net Income	$240.53M
Cost of Goods Sold	$150.09M
Gross Profit	$675.32M
Operating Expenses	$548.52M
Operating Income	$276.89M
Non-Operating Income/Expense	$20.98M
Pre-Tax Income	$297.87M
Normalized Pre-Tax Income	$297.87M
Income after Taxes	$240.53M
Income from Continuous Operations	$240.53M
Consolidated Net Income/Loss	$240.53M
Normalized Income after Taxes	$240.53M
EBIT	$276.89M
EBITDA	$294.10M
Weighted-Average Shares Outstanding (Basic)	191.91M
Weighted-Average Shares Outstanding (Diluted)	197.09M
Earnings per Share (EPS) (Basic)	$1.25
Earnings per Share (EPS) (Diluted)	$1.23
Balance Sheet Financials
Current Assets	$3.81B
Property, Plant, and Equipment	$1.03B
Long-Term Assets	$3.65B
Total Assets	$7.46B
Current Liabilities	$684.25M
Long-Term Debt	$596.16M
Long-Term Liabilities	$744.98M
Total Liabilities	$1.43B
Common Equity	$6.03B
Tangible Shareholders Equity	$5.59B
Shareholders Equity	$6.03B
Common Shares Outstanding	192.00M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$359.67M
Cash Flow from Investing Activities	$-40.83M
Cash Flow from Financial Activities	$-43.38M
Beginning Cash	$942.84M
End Cash	$1.21B
Increase/Decrease in Cash	$270.97M
Stock-Based Compensation	$85.23M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.56
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.09
Debt to Equity Ratio	0.10
Gross Margin	81.82%
Operating Margin	33.55%
EBIT Margin	33.55%
EBITDA Margin	--
Pre-Tax Profit Margin	36.09%
Profit Margin	29.14%
Free Cash Flow	$325.80M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.11
Inventory Turnover	0.11
Receiveable Turnover	0.96
Days Sales in Receivables	93.32
Return on Equity	3.99%
Return on Tangible Equity	4.30%
Return on Assets	3.23%
Return on Investments	3.63%
Book Value Per Share	$31.39
Free Cash Flow per Share	$1.65
Operating Cash Flow per Share	$1.82

Data from Zacks Investment Research, Inc.